Title
Interplay Between Immune and Cancer-Associated Fibroblasts: A Path to Target Metalloproteinases in Penile Cancer
Date Issued
19 July 2022
Access level
open access
Resource Type
journal article
Author(s)
Cury S.S.
Kuasne H.
Souza J.d.S.
da Silva J.P.
Lopes A.
Scapulatempo-Neto C.
Faria E.F.
Delaissé J.M.
Marchi F.A.
Rogatto S.R.
Publisher(s)
Frontiers Media S.A.
Abstract
Extracellular matrix (ECM) remodeling and inflammation have been reported in penile carcinomas (PeCa). However, the cell types and cellular crosstalk involved in PeCa are unexplored. We aimed to characterize the complexity of cells and pathways involved in the tumor microenvironment (TME) in PeCa and propose target molecules associated with the TME. We first investigated the prognostic impact of cell types with a secretory profile to identify drug targets that modulate TME-enriched cells. The secretome analysis using the PeCa transcriptome revealed the enrichment of inflammation and extracellular matrix pathways. Twenty-three secreted factors were upregulated, mainly collagens and matrix metalloproteinases (MMPs). The deregulation of collagens and MMPs was confirmed by Quantitative reverse transcription - polymerase chain reaction (RT-qPCR). Further, the deconvolution method (digital cytometry) of the bulk samples revealed a high proportion of macrophages and dendritic cells (DCs) and B cells. Increased DCs and B cells were associated with better survival. A high proportion of cancer-associated fibroblasts (CAFs) was observed in low-survival patients. Patients with increased CAFs had decreased immune cell proportions. The treatment with the MMP inhibitor GM6001 in CAF cells derived from PeCa resulted in altered cell viability. We reported a crosstalk between immune cells and CAFs, and the proportion of these cell populations was associated with prognosis. We demonstrate that a drug targeting MMPs modulates CAFs, expanding the therapeutic options of PeCa.
Volume
12
Language
English
OCDE Knowledge area
Oncología
Scopus EID
2-s2.0-85135258233
Source
Frontiers in Oncology
Sponsor(s)
The authors would like to acknowledge Barretos Cancer Hospital and A.C.Camargo Cancer Center, SP, Brazil, for providing human specimens. This work was supported by the National Institute of Science and Technology in Oncogenomics (São Paulo Research Foundation – FAPESP: #2008/57887-9 and the National Council for Scientific and Technological Development – CNPq: #573589/08-9), and the Research Council of Lillebaelt Hospital, Denmark.
Sources of information: Directorio de Producción Científica Scopus